Table 2.
Phase I clinical trials with anti-CD20 radiolabelled monoclonal antibodies for relapsed and transformed indolent B-cell lymphoma [30, 31]
| I-131 tositumomab | Y-90 ibritumomab tiuxetan | |
|---|---|---|
| Number of patients | 59 | 57 |
| Median age of patients, years | 50 | 60 |
| Patient population: percent low-grade or transformed | 71 | 67 |
| Dose range | 25–75 cGy TBI | 0.2–0.4 mCi/kg |
| Maximum tolerated dose | 75 cGy TBI | 0.4 mCi/kg |
| Dose limiting toxicity | Haematologic pancytopenia | Haematologic pancytopenia |
| Response rate, % | 71 | 67 |
| Median duration response, months | 9 | 12 |
| Complete response rate, % | 34 | 25 |